ABSTRACT
The use of modern chemotherapy (CT) allowed to achieve significant progress in the treatment of many malignant tumors that were previously considered fatal. Improving the efficiency of the treatment was achieved by the intensification of chemotherapy. However, intensification of chemotherapy regimes provoked increase in the number of side effects of anticancer therapy,which often lead to a decrease in the intensity of the selected mode, the additional financial costs of treating the complications and the formation of the negative attitude of the patient to treatment. Thus, the side effects of chemotherapy are the actual problem of modern oncology. The purpose of this literature review was to investigate the frequency, symptoms and ways to prevent and treat various types of toxicity of chemotherapy.
Subject(s)
Antineoplastic Agents/adverse effects , Chemical and Drug Induced Liver Injury/drug therapy , Nausea/drug therapy , Neutropenia/drug therapy , Protective Agents/therapeutic use , Vomiting/drug therapy , Antineoplastic Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Breast Neoplasms/pathology , Chemical and Drug Induced Liver Injury/diagnosis , Chemical and Drug Induced Liver Injury/metabolism , Female , Humans , Nausea/chemically induced , Nausea/diagnosis , Nausea/metabolism , Neutropenia/chemically induced , Neutropenia/diagnosis , Neutropenia/metabolism , Receptors, Serotonin/metabolism , Serotonin Antagonists/therapeutic use , Vomiting/chemically induced , Vomiting/diagnosis , Vomiting/metabolismABSTRACT
Management of non-Hodgkin's lymphomas (NHL) has been significantly changed during last 40 years from radiotherapy to modern polychemotherapy with application of monoclonal antibodies. A ten year experience of the treatment of patients with B-cell NHL with rituximab application was accumulated in National Cancer Institute. The group of patients with NHL, who were treated in oncohematology department in the period from 2001 to 2010, was chosen for study of the efficacy of the treatment with rituximab. The immediate and distant results of the treatment were evaluated in this group of patients. The usage of the polychemotherapy with rituximab was highly efficient in the treatment of primary and relapsed patients with NHL. This group shows high rate of the immediate and distant results of treatment.
Subject(s)
Antibodies, Monoclonal, Murine-Derived/therapeutic use , Antigens, CD20/immunology , Antineoplastic Agents/therapeutic use , B-Lymphocytes/immunology , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/immunology , Secondary Prevention , Adult , Aged , Antibodies, Monoclonal, Murine-Derived/administration & dosage , Antigens, CD20/metabolism , Antineoplastic Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , B-Lymphocytes/cytology , Biopsy , Disease-Free Survival , Drug Administration Schedule , Female , Humans , Longitudinal Studies , Lymphoma, Non-Hodgkin/mortality , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Rituximab , T-Lymphocytes/cytology , T-Lymphocytes/immunology , Treatment Outcome , UkraineABSTRACT
Achievements of world practice about development and prophilaxis of tromboembolic events (VTE) in cancer patients. Particular attention is paid to prevention of VTE in patients with multiply myeloma who receive chemotherapy with Thalidomide.
Subject(s)
Fibrinolytic Agents/administration & dosage , Multiple Myeloma/drug therapy , Thalidomide/adverse effects , Thrombosis/drug therapy , Age Factors , Aspirin/administration & dosage , Aspirin/therapeutic use , Clinical Trials as Topic , Drug Combinations , Enoxaparin/administration & dosage , Enoxaparin/therapeutic use , Fibrinolytic Agents/therapeutic use , Humans , Multiple Myeloma/complications , Multiple Myeloma/physiopathology , Risk Factors , Severity of Illness Index , Thalidomide/administration & dosage , Thalidomide/therapeutic use , Thrombosis/complications , Thrombosis/physiopathology , Warfarin/administration & dosage , Warfarin/therapeutic useABSTRACT
The treatment of patients with refractory forms of Hodgkin's lymphomas in combination with chemo-radiotherapy is priority. Nevertheless, chemotherapy has to include multicomponent schemes and radiation therapy should be an addition and consolidative method to chemotherapy.
